|
|
| NSW Cancer Proteomics Research |
The award of a Cancer Institute NSW research infrastructure grant has provided an advanced mass spectrometry capability at APAF dedicated to supporting cancer proteomics research in NSW. The grant has allowed for the acquisition of a hybrid triple quadrupole/linear ion trap mass spectrometer (4000 QTRAP, Applied Biosystems) and dedicated nanoflow liquid chromatography instrumentation (NanoLC-2D, Eksigent). The 4000 QTRAP is well suited to many proteomic applications given its high-sensitivity MS, MS/MS and MS3 scans, and true triple quadrupole precursor ion (PI), neutral loss (NL), and multiple reaction monitoring (MRM) capabilities. The instrument is used for a variety of purposes including phosphopeptide analysis (PI and NL scans) and protein quantification (MRM), providing much needed MS capabilities to support the research activities of eight cancer researchers in NSW including:
- Prof. Mark Baker (APAF and Dept. of Chemistry and Biomolecular Sciences, Macquarie University)
- Prof. Robert Baxter (Kolling Insitute of Medical Research, Dept. of Molecular Medicine, University Of Sydney)
- Prof. Richard Christopherson (School of Molecular and Microbial Biosciences, University Of Sydney)
- Prof. Stephen Clarke (Concord Repatriation Hospital)
- Assoc. Prof. Roger Daly (Garvan Institute of Medical Research and Faculty of Medicine, University of NSW)
- Assoc. Prof. Michael Guilhaus (Bioanalytical Mass Spectrometry Facility, University of NSW)
- Dr Maria Kavallaris (Children’s Cancer Institute Australia)
- Dr Mark Molloy (APAF)
| |
|
|
|
|
|
|
| |
|
|